Nazanin K Majd (Nazanin Majd)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Cerebrospinal Fluid

Intellectual Disability

Newly Diagnosed

Top Venues

Journal of gastrointestinal oncology

JCO precision oncology

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Keng Lam, Carlos Kamiya-Matsuoka, John M Slopis, Ian E McCutcheon, Nazanin K Majd
Therapeutic Strategies for Gliomas Associated With Cancer Predisposition Syndromes. JCO precision oncology 8 (2024)
Nazanin K Majd, Henry Hiep Vo, Cesar A Moran, Shiao-Pei Weathers, I-Wen Song, Garret L Williford, Jordi Rodon Ahnert, Siqing Fu, Apostolia-Maria Tsimberidou
Metastatic extraneural glioblastoma diagnosed with molecular testing. The oncologist (2024)
Cindy M Pabon, Debra Nana Yeboa, Barbara J O'Brien, Nazanin K Majd, Chenyang Wang, Mariela Blum Murphy
Intrathecal topotecan with systemic checkpoint inhibitor therapy for gastroesophageal cancer with leptomeningeal involvement: two case reports and review of the literature. Journal of gastrointestinal oncology 15 (3) (2024)
Lily C Pham, Lauryn Weller, Claudia N Gann, Karl Maria Schumacher, Soetkin Vlassak, Todd Swanson, Kaitlin Highsmith, Barbara J O'Brien, Sebnem Nash, Ashley Aaroe, John F de Groot, Nazanin K Majd
Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion. The oncologist (2024)
Cindy M Pabon, Debra Nana Yeboa, Barbara J O'Brien, Nazanin K Majd, Chenyang Wang, Mariela Blum Murphy
Intrathecal topotecan with systemic checkpoint inhibitor therapy for gastroesophageal cancer with leptomeningeal involvement: two case reports and review of the literature. Journal of gastrointestinal oncology 15 (3) (2024)
Nazanin K Majd, Steven G Waguespack, Filip Janku, Siqing Fu, Marta Penas-Prado, Mingxuan Xu, Anas Alshawa, Carlos Kamiya-Matsuoka, Shaan M Raza, Ian E McCutcheon, Aung Naing
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. Journal for immunotherapy of cancer 8 (2) (2021)